FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988439540> ?p ?o ?g. }

• W1988439540 abstract "Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, ILThe use of tyrosine kinase inhibitors (TKI) to target oncogenic kinases has led to remarkable responses in patients with chronic myeloid leukemia (CML) and EGFR-mutated non-small cell lung cancer (EGFR NSCLC). However, a significant subset of patients have a minimal or very brief response. It has been suggested that germline polymorphisms may account for this upfront TKI resistance, and that identifying such polymorphisms will allow personalization of targeted therapy to achieve optimal responses in patients. Using paired-end DNA sequencing, we discovered a common (12.3% carrier rate) deletion polymorphism in intron 2 of the BIM gene. BIM is a pro-apoptotic member of the BCL2 family of proteins, and is required for TKIs to induce apoptosis in many cancers. We investigated the effects of the polymorphism on BIM function and TKI resistance in CML and EGFR NSCLC. Inspection of BIM gene structure suggested the polymorphism would result in mutually exclusive splicing of exon 3 (E3) and 4 (E4). Importantly, such an event is predicted to affect TKI sensitivity, since the pro-apoptotic BH3 domain is found only in E4. Using minigenes, we confirmed the deletion favored splicing of E3 over E4 by 5-fold (p=0.008), and that the deletion contained a cis-acting splicing suppressor. Next, using Zn finger nuclease-editing, we recreated the polymorphism in TKI sensitive CML (K562) and EGFR NSCLC (PC9) cell lines. Polymorphism-containing subclones had increased E3/E4 transcript ratios, decreased expression of BH3-containing BIM protein and defective apoptotic signaling, and were intrinsically TKI resistant. Importantly, while manipulation of E3-containing transcript levels did not alter the resistance phenotype, pharmacologic restoration of BH3 function (using a BH3 mimetic ABT-737) restored apoptotic signaling as well as TKI-sensitivity. Finally, we determined if the polymorphism predicted for inferior clinical responses in TKI-treated CML and EGFR NSCLC patients. In 203 CML patients, the polymorphism predicted inferior imatinib responses (defined by EuropeanLeukemiaNet criteria) among those with the polymorphism vs those without (odds ratio=2.94, p=0.02, 95% CI 1.17-7.43). In 141 EGFR NSCLC patients, the polymorphism predicted a shorter PFS of 6.6 vs 11.9 months (p=0.0027), and was independently prognostic for poorer PFS (hazard ratio=2.14, p=0.0026, 95% CI 1.30-3.50). In summary, by altering BIM splicing, the BIM polymorphism is sufficient to cause intrinsic TKI resistance in vitro, and predicts inferior TKI responses in patients. Upfront testing of CML and EGFR NSCLC patients for the BIM polymorphism may identify individuals at risk for developing clinical TKI resistance. Our results also offer an explanation for the heterogeneity of TKI responses among CML and EGFR NSCLC patients, and suggest the possibility of personalizing therapy with BH3 mimetics to improve TKI responses.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1911. doi:1538-7445.AM2012-1911" @default.
• W1988439540 created "2016-06-24" @default.
• W1988439540 creator A5000523815 @default.
• W1988439540 creator A5000754700 @default.
• W1988439540 creator A5001032768 @default.
• W1988439540 creator A5001952637 @default.
• W1988439540 creator A5002497469 @default.
• W1988439540 creator A5004806561 @default.
• W1988439540 creator A5012677471 @default.
• W1988439540 creator A5016601323 @default.
• W1988439540 creator A5017520870 @default.
• W1988439540 creator A5019732433 @default.
• W1988439540 creator A5020529174 @default.
• W1988439540 creator A5026798946 @default.
• W1988439540 creator A5027104050 @default.
• W1988439540 creator A5028165330 @default.
• W1988439540 creator A5028790437 @default.
• W1988439540 creator A5032293215 @default.
• W1988439540 creator A5032419673 @default.
• W1988439540 creator A5032833474 @default.
• W1988439540 creator A5033849876 @default.
• W1988439540 creator A5035069362 @default.
• W1988439540 creator A5039672834 @default.
• W1988439540 creator A5042877889 @default.
• W1988439540 creator A5044860914 @default.
• W1988439540 creator A5048208940 @default.
• W1988439540 creator A5049861606 @default.
• W1988439540 creator A5050496878 @default.
• W1988439540 creator A5052533761 @default.
• W1988439540 creator A5053502496 @default.
• W1988439540 creator A5055510705 @default.
• W1988439540 creator A5059269204 @default.
• W1988439540 creator A5061589915 @default.
• W1988439540 creator A5062774997 @default.
• W1988439540 creator A5066282840 @default.
• W1988439540 creator A5072258594 @default.
• W1988439540 creator A5072559424 @default.
• W1988439540 creator A5072702184 @default.
• W1988439540 creator A5073548226 @default.
• W1988439540 creator A5073591697 @default.
• W1988439540 creator A5075641646 @default.
• W1988439540 creator A5077963178 @default.
• W1988439540 creator A5078535679 @default.
• W1988439540 creator A5080242797 @default.
• W1988439540 creator A5080656059 @default.
• W1988439540 creator A5081294763 @default.
• W1988439540 creator A5084019255 @default.
• W1988439540 creator A5085137987 @default.
• W1988439540 creator A5087462165 @default.
• W1988439540 creator A5090560513 @default.
• W1988439540 creator A5091235988 @default.
• W1988439540 creator A5063242382 @default.
• W1988439540 date "2012-04-15" @default.
• W1988439540 modified "2023-10-10" @default.
• W1988439540 title "Abstract 1911: A common BIM polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer" @default.
• W1988439540 doi "https://doi.org/10.1158/1538-7445.am2012-1911" @default.
• W1988439540 hasPublicationYear "2012" @default.
• W1988439540 type Work @default.
• W1988439540 sameAs 1988439540 @default.
• W1988439540 citedByCount "0" @default.
• W1988439540 crossrefType "proceedings-article" @default.
• W1988439540 hasAuthorship W1988439540A5000523815 @default.
• W1988439540 hasAuthorship W1988439540A5000754700 @default.
• W1988439540 hasAuthorship W1988439540A5001032768 @default.
• W1988439540 hasAuthorship W1988439540A5001952637 @default.
• W1988439540 hasAuthorship W1988439540A5002497469 @default.
• W1988439540 hasAuthorship W1988439540A5004806561 @default.
• W1988439540 hasAuthorship W1988439540A5012677471 @default.
• W1988439540 hasAuthorship W1988439540A5016601323 @default.
• W1988439540 hasAuthorship W1988439540A5017520870 @default.
• W1988439540 hasAuthorship W1988439540A5019732433 @default.
• W1988439540 hasAuthorship W1988439540A5020529174 @default.
• W1988439540 hasAuthorship W1988439540A5026798946 @default.
• W1988439540 hasAuthorship W1988439540A5027104050 @default.
• W1988439540 hasAuthorship W1988439540A5028165330 @default.
• W1988439540 hasAuthorship W1988439540A5028790437 @default.
• W1988439540 hasAuthorship W1988439540A5032293215 @default.
• W1988439540 hasAuthorship W1988439540A5032419673 @default.
• W1988439540 hasAuthorship W1988439540A5032833474 @default.
• W1988439540 hasAuthorship W1988439540A5033849876 @default.
• W1988439540 hasAuthorship W1988439540A5035069362 @default.
• W1988439540 hasAuthorship W1988439540A5039672834 @default.
• W1988439540 hasAuthorship W1988439540A5042877889 @default.
• W1988439540 hasAuthorship W1988439540A5044860914 @default.
• W1988439540 hasAuthorship W1988439540A5048208940 @default.
• W1988439540 hasAuthorship W1988439540A5049861606 @default.
• W1988439540 hasAuthorship W1988439540A5050496878 @default.
• W1988439540 hasAuthorship W1988439540A5052533761 @default.
• W1988439540 hasAuthorship W1988439540A5053502496 @default.
• W1988439540 hasAuthorship W1988439540A5055510705 @default.
• W1988439540 hasAuthorship W1988439540A5059269204 @default.
• W1988439540 hasAuthorship W1988439540A5061589915 @default.
• W1988439540 hasAuthorship W1988439540A5062774997 @default.
• W1988439540 hasAuthorship W1988439540A5063242382 @default.
• W1988439540 hasAuthorship W1988439540A5066282840 @default.
• W1988439540 hasAuthorship W1988439540A5072258594 @default.
• W1988439540 hasAuthorship W1988439540A5072559424 @default.
• W1988439540 hasAuthorship W1988439540A5072702184 @default.
• W1988439540 hasAuthorship W1988439540A5073548226 @default.
• W1988439540 hasAuthorship W1988439540A5073591697 @default.

• next